ARTICLE | Company News
Revlimid: first approval in China, Priority Review in U.S. for MCL
February 12, 2013 12:49 AM UTC
Celgene Corp. (NASDAQ:CELG) said China's State Food and Drug Administration (SFDA) approved Revlimid lenalidomide in combination with dexamethasone to treat relapsed or refractory multiple myeloma (MM) in patients who have received at least one prior therapy. This is Revlimid's first approval in China. Celgene, which markets Revlimid in the U.S. and EU for the indication and in the U.S. to treat patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS), expects to launch the product in China next quarter. ...